Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.955 SEK | +2.25% | -26.12% | -61.42% |
Apr. 15 | Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain | CI |
Apr. 04 | Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024 | CI |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-61.42% | 26.62M | C+ | ||
-2.31% | 103B | B+ | ||
+0.56% | 95.28B | B+ | ||
+1.69% | 22.15B | B | ||
-17.37% | 21.02B | B+ | ||
-9.30% | 18.15B | A- | ||
-41.01% | 16.73B | A- | ||
-14.85% | 16.05B | B | ||
+3.21% | 13.68B | C+ | ||
+33.54% | 12.17B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ONCO Stock
- Ratings Oncopeptides AB